

GURZU SIMONA

**LISTA DE VERIFICARE CRITERII MINIMALE pentru panel 3, comisia medicina
(conform Ordinului MECS – 4478/23.06.2011)**

Nr.	Referinta bibliografica	S_i	n_i	p_i	S_i/n_i	S_i/p_i
1.	Gurzu S , Tivadar B, Jung I. Inflammatory myofibroblastic tumor in the colon. Case report and hypothesis about its histogenesis. <i>Journal of Clinical Oncology</i> . 2013. DOI:10.1200/JCO.2012.42.8961. Factor impact 18.372	6.36306	3	1	2.121	6.36306
2.	Gurzu S , Szentirmay Z, Bara T, Turcu M, Toth E, Bara T jr., Jung I. Non-Epstein-Barr virus associated lymphoepithelioma-like carcinoma of the esophagogastric junction with microsatellite instability, K-ras wild type. <i>Pathology Research Practice</i> . 2013. DOI:10.1016/j.prp.2012.11.004. Factor impact 1.213	0.65268	7	1	0.0932	0.65268
3.	Gurzu S , Gozar H, Derzsi Z, Szabo B, Jung I. Second case of a fetal sacrococcygeal neuroectodermal cyst in a male newborn. <i>Pathology</i> . 2013. DOI: 10.1097/PAT.0b013e32835c7804. Factor impact 2.378	1.17617	5	1	0.2352	1.17617
4.	Gurzu S , Szentirmay Z, Toth E, Jung I. Possible predictive value of Maspin expression in colorectal cancer. <i>Recent patents on anti-cancer drug discovery</i> . May 2013. In press. 8(2):... Factor impact 2.723	1.13445	4	1	0.2836	1.13445
5.	Gurzu S , Cimpean AM, Kovacs J, Jung I. Counting of angiogenesis in colorectal carcinomas using double immunostain. <i>Tumori</i> . 2012. 98(4):485-490. Factor impact 0.606	0.31847	4	1	0.0796	0.31847
6.	Kovacs J, Gurzu S , Jung J, Szederjesi J, Copotoiu SM, Copotoiu R, Azamfirei L. Clinico-pathological particularities of the shock-related pancreatitis. <i>Pathology Oncology Research</i> . 2012. 18:977-981. Factor impact 1.366. Corresponding author.	0.69966	7	1	0.0999	0.69966
7.	Gurzu S , Jung I. Male breast cellular myofibroblastoma with a rich reticuline network – case report. <i>American Journal of Men's health</i> . 2012. 6(4):344-348. Factor impact 1.152	0.61830	2	1	0.3091	0.61830
8.	Gurzu S , Jung I. Aberrant pattern of the Cytokeratin 7/Cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. <i>Pathology Research Practice</i> . 2012. 208(3):163-166. Factor impact 1.213	0.65268	2	1	0.3263	0.65268
Total					I	P
					3.5479	11.6154

Criterii minime cerute: $I \geq 2$ si $P \geq 3$.